Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430403 | 1.00 | MTNR1A (0.53) | MTNR1AMTNR1BRIPK1GRM7NOTUM | |
| SCHEMBL2981090 | 0.78 | HPGD (0.52) | MTNR1AMTNR1BNPC1LMNARAB9A | |
| Hydrochloric Acid SCHEMBL26113748 | 0.78 | SLC6A2 (0.52) | MTNR1AMTNR1BRIPK1NOTUM | |
| SCHEMBL429257 | 0.77 | MTNR1A (0.77) | MTNR1AMTNR1BTEAD1 | |
| SCHEMBL429595 | 0.77 | TEAD1 (0.44) | NOTUMTEAD1 | |
| SCHEMBL10384510 | 0.76 | MAPT (0.57) | MTNR1AMTNR1BNOTUM | |
| SCHEMBL9851524 | 0.76 | GRM7 (0.59) | MTNR1AMTNR1BGRM7NPC1LMNA | |
| SCHEMBL25332406 | 0.75 | MTNR1A (0.62) | MTNR1AMTNR1BGRM7LMNA | |
| SCHEMBL25333283 | 0.74 | MTNR1A (0.61) | MTNR1AMTNR1BLMNA | |
| SCHEMBL25330960 | 0.74 | POLB (0.55) | MTNR1AMTNR1BNPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE40278-E1 | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 2008-04-29 | — | — | US | claimed |
| US-20010009916-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | ROMERO ARTHUR G (US) | 2001-07-26 | — | — | US | claimed |
| US-RE40278-E1 | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| US-7074927-B2 | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 2006-07-11 | — | — | US | disclosed |
| US-20050107378-A1 | Heterocyclic amines having central nervous system activity | ROMERO ARTHUR G (US) | 2005-05-19 | — | — | US | disclosed |
| US-RE38452-E1 | SUITABLE FOR TREATING ANXIOLYTIC DISORDER, SCHIZOPHRENIA, PARKINSON'S DISEASE, ANXIETY | PHARMACIA & UPJOHN COMPANY | 2004-03-02 | — | — | US | disclosed |
| US-20010009916-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | ROMERO ARTHUR G (US) | 2001-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009916-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | CNR1, CNR2, OPRD1 | MTNR1A 64/4885MTNR1B 91/4885RIPK1 4296/4885 |
| US-20050107378-A1 | Heterocyclic amines having central nervous system activity | CNR1, CNR2, NPY2R | MTNR1A 77/4885MTNR1B 109/4885RIPK1 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.